Humanized mouse models for the preclinical evaluation of novel immune cell therapies, check point inhibitors, and immune cell engagers

被引：0
|
作者：
Stecklum, Maria [1 ]
Wulf-Goldenberg, Annika [1 ]
Alcaniz, Joshua [1 ]
Brzezicha, Bernadette [1 ]
Wolfgang, Walther [1 ,2 ]
Hoffmann, Jens [1 ]
机构：
[1] EPO GmbH, Berlin, Germany
[2] Charite Univ Med Berlin, ECRC, Berlin, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2024年 / 47卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
600
引用
收藏
页码：222 / 223
页数：2
相关论文
共 50 条
  • [41] Optimal timing for combined therapy with axitinib and immune check point inhibitor in a mouse renal cell carcinoma model
    Watanabe, Hiromitsu
    Kawakami, Asuka
    Sato, Ryo
    Watanabe, Kyohei
    Matsushita, Yuto
    Motoyama, Daisuke
    Ito, Toshiki
    Sugiyama, Takayuki
    Otsuka, Atsushi
    Miyake, Hideaki
    CANCER SCIENCE, 2022, 113 : 1720 - 1720
  • [42] Humanized Mouse Models to Study Cell-Mediated Immune Responses to Liver-Stage Malaria Vaccines
    Good, Michael F.
    Hawkes, Michael T.
    Yanow, Stephanie K.
    TRENDS IN PARASITOLOGY, 2015, 31 (11) : 583 - 594
  • [43] Evaluation of fruquintinib, a potent and selective oral VEGFR inhibitor, in combination with targeted therapies or immune checkpoint inhibitors in preclinical tumor models
    Ren, Yongxin
    Sun, Qiaoling
    Long, Jingwen
    Fan, Shiming
    Tang, Renxiang
    Zhang, Wei
    Ge, Xuelei
    Tang, Jianxing
    Wang, Linfang
    Shi, Dongxia
    Chen, Hongbo
    Cheng, Min
    Qing, Weiguo
    Su, Weiguo
    CANCER RESEARCH, 2017, 77
  • [44] Humanized Mice Are Precious Tools for Preclinical Evaluation of CAR T and CAR NK Cell Therapies
    Mhaidly, Rana
    Verhoeyen, Els
    CANCERS, 2020, 12 (07) : 1 - 22
  • [45] An advanced approach technique for tracking point between immune check point inhibitor and cancer cell mechanism in immune response motility by infiltration a breast cancer cell
    Kim, Hyunseok
    Ahn, Soyeon
    Kwon, Hyungjin
    Chen, Hsuan-Ju
    Park, Inwon
    Kim, Pilhan
    Kubra, Akyildiz
    CANCER RESEARCH, 2023, 83 (07)
  • [46] The toxicity associated with combining immune check point inhibitors with tyrosine kinase inhibitors in patients with non-small cell lung cancer
    Kalra, Anjali
    Rashdan, Sawsan
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [47] Financial Toxicity and Non-small Cell Lung Cancer Treatment: The Optimization in the Choice of Immune Check Point Inhibitors
    Giuliani, Jacopo
    Bonetti, Andrea
    ANTICANCER RESEARCH, 2019, 39 (07) : 3961 - 3965
  • [48] A novel Pik3ca-driven mouse model and syngeneic cancer cell line for the preclinical testing of targeted and immune therapies for anal squamous cell carcinoma (ASCC)
    Guerra, Glen R.
    Roth, Sara
    Kong, Joseph C.
    Millen, Rosemary M.
    Liu, David S.
    Sampurno, Shienny
    Narasimhan, Vignesh
    Pham, Toan D.
    Montgomery, Karen G.
    Heriot, Alexander G.
    Ramsay, Robert G.
    Phillips, Wayne A.
    CANCER RESEARCH, 2019, 79 (13)
  • [49] Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer
    Genova, Carlo
    Rossi, Giovanni
    Rijavec, Erika
    Biello, Federica
    Barletta, Giulia
    Tagliamento, Marco
    Grossi, Francesco
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (05) : 573 - 585
  • [50] Preclinical evaluation of new therapies using a novel mouse model of pancreatic cancer which recapitulates the tumor stromal and immune microenvironment
    Majumder, Kaustav
    Modi, Shrey
    Chugh, Rohit K.
    Banerjee, Sulagna
    Saluja, Ashok
    Dudeja, Vikas
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2015, 221 (04) : E21 - E22
12345